Pancreatic Cancer Research

ResearcherAzienda Ospedaliero-Universitaria CareggiActive in the last 2 years

Elisa Giommoni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1715-8440; OpenAlex author ID A5064858820. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 5 papers · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 16

  1. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  2. The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 20… First author DOI 10.1186/s13045-026-01834-2↗
  3. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  4. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… Co-author DOI 10.1016/j.dld.2025.11.007↗
  5. Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional … Co-author DOI 10.1016/j.esmoop.2024.104001↗
  6. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
  7. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  8. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  9. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  10. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  11. Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine. Last author DOI 10.3390/cancers15020416↗
  12. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Co-author DOI 10.1016/j.critrevonc.2021.103571↗
  13. Isoforms of the orphan nuclear receptor COUP‑TFII differentially modulate pancreatic cancer progression. Co-author DOI 10.3892/ijo.2022.5345↗
  14. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  15. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Co-author DOI 10.3390/curroncol28030164↗
  16. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by th… Co-author DOI 10.3390/cancers12061681↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michèle Milella · 9 shared papers, 2020–2025 · strength 1.21
  2. Guido Giordano · 8 shared papers, 2021–2026 · strength 1.11
  3. Letizia Procaccio · 7 shared papers, 2023–2026 · strength 1.09
  4. Giampaolo Tortora · 7 shared papers, 2021–2026 · strength 0.97
  5. Michele Reni · 7 shared papers, 2020–2025 · strength 0.93
  6. Lorenzo Antonuzzo · 5 shared papers, 2021–2026 · strength 0.93
  7. Monica Niger · 6 shared papers, 2021–2026 · strength 0.87
  8. Silvia Bozzarelli · 6 shared papers, 2021–2025 · strength 0.86
  9. Enrico Vasile · 6 shared papers, 2020–2026 · strength 0.86
  10. Marina Macchini · 6 shared papers, 2021–2025 · strength 0.83
  11. Francesca Bergamo · 5 shared papers, 2023–2026 · strength 0.80
  12. Sara Lonardi · 5 shared papers, 2023–2026 · strength 0.76
  13. Mario Scartozzi · 5 shared papers, 2021–2026 · strength 0.70
  14. Giulia Orsi · 5 shared papers, 2021–2025 · strength 0.70
  15. Ilario Giovanni Rapposelli · 5 shared papers, 2021–2025 · strength 0.67
  16. Ferdinando De Vita · 4 shared papers, 2022–2026 · strength 0.61
  17. Lisa Salvatore · 4 shared papers, 2023–2025 · strength 0.58
  18. Mariacristina Di Marco · 4 shared papers, 2021–2026 · strength 0.57
  19. Ingrid Garajová · 4 shared papers, 2021–2025 · strength 0.53
  20. Stefano Cascinu · 4 shared papers, 2021–2025 · strength 0.51
  21. Davide Melisi · 3 shared papers, 2023–2026 · strength 0.48
  22. Alberto Zaniboni · 3 shared papers, 2023–2026 · strength 0.48
  23. Alessandro Bittoni · 4 shared papers, 2020–2025 · strength 0.47
  24. Caterina Vivaldi · 3 shared papers, 2021–2026 · strength 0.47
  25. Andrea Galli · 2 shared papers, 2022–2026 · strength 0.44

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.